Navigation Links
Medisafe 1 Technologies Pre-pays Additional 2 Convertible Promissory Notes Due in Full to Avoid Dilution to Shareholders
Date:11/4/2011

JERUSALEM, November 4, 2011 /PRNewswire/ --

Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company has pre-paid two convertible promissory notes aggregating $57,000, including the interest due.

The notes beared interest at 8% per annum and were due in August , 2011 and in October , 2011. The notes had conversion rights allowing the holder of the note at any time to convert all or any part of the remaining principal balance into the Company's common stock at a price equal to 58% of the average of the lowest three trading prices for the Common Stock during the most recent ten-day period.

The note was issued to fund development of Medisafe 1's patented life-saving technology and to assist in ongoing business development. As a result of pre-payment, the non-affiliated third party lender has released Medisafe 1 Technologies from its obligation. "Medisafe 1 pre-paid the promissory notes to prevent the notes from being converted into equity," said Jacob Elhadad, CEO of Medisafe 1 Technologies Corp. "Pre-payment of the notes prevented and continues to prevent the dilution of our common stock."

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.

Contact:
Jacob Elhadad
CEO
+972-524440000
Jacob.elhadad10@gmail.com



'/>"/>
SOURCE Medisafe 1 Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company
2. Medisafe 1 Technologies Finalises Contract to Develop Prototype of the Worlds First Ever Medicinal Syringe-Locking Device
3. Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend
4. Medisafe 1 Technologies Corp Notify Shareholders on FINRAs Approval of the 5-1 Stock Dividend
5. Medisafe 1 Technologies Successfully Tests Prototype of Patented Syringe Locking Device
6. Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference
7. Medisafe 1 Technologies Presentation on Newly Launched Company Website
8. Medisafe 1 Technologies to Exhibit at Worlds Largest Medical Conference
9. Medisafe 1 Technologies Exhibition Generates Remarkable Interest at HealthAchieve Conference
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... , May 10, 2017 Radiology has become ... its costs have also spiraled to the number one ... to radiology than ever before as the most complete ... a patient with lower back pain an MRI may ... reason for pain, resulting in entirely different treatment protocols.  ...
(Date:5/9/2017)...  Semler Scientific, Inc. (OTCQB: SMLR), an emerging ... the clinical effectiveness and efficiency of healthcare providers, ... ended March 31, 2017. "We ... identify when preventive care options are appropriate, which ... attacks or strokes occur," said Doug Murphy-Chutorian ...
(Date:5/6/2017)...  Hill-Rom Holdings, Inc. (NYSE: HRC), has begun a ... to its Welch Allyn campus. The ... more than 100 new jobs to Central ... a significant presence for more than 100 years. Hill-Rom,s ... large portion of which will be R&D and engineering ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Leading ... 2017 on May 30th and 31st at The Four Seasons Hotel Boston. ... in the life sciences, offering exclusive access to key decision makers who influence ...
(Date:5/26/2017)... ... May 26, 2017 , ... Amir Qureshi, MD is the first physician ... spinal cord stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as ... the first in Arkansas to introduce the most powerful SCS system and the only ...
(Date:5/26/2017)... ... ... A new analysis of community health data reveals that four out of the ... the average cost of healthcare rising and the U.S. senior population expected to double ... of where they live. An annual 2017 report looked at a variety of community ...
(Date:5/26/2017)... ... 26, 2017 , ... via seating is proud to partner ... chair specifically designed for clinical areas. Genie Copper Mesh is a crossover chair ... to provide customers with a game changing chair that is affordably priced,” Chas ...
(Date:5/26/2017)... ... May 26, 2017 , ... After raising nearly $30,000 on Kickstarter ... to be available at a discounted crowdfunding price on Indiegogo . , “Along ... I also wanted to bring a fidget toy to the market that was made ...
Breaking Medicine News(10 mins):